caa a22 4500 60615745X CHVBK 20210128100613.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s10096-015-2399-5 doi (NATIONALLICENCE)springer-10.1007/s10096-015-2399-5 Application of immobilized synthetic anti-lipopolysaccharide peptides for the isolation and detection of bacteria [Elektronische Daten] [N. Sandetskaya, B. Engelmann, K. Brandenburg, D. Kuhlmeier] The molecular detection of microorganisms in liquid samples generally requires their enrichment or isolation. The aim of our study was to evaluate the capture and pre-concentration of bacteria by immobilized particular cationic antimicrobial peptides, called synthetic anti-lipopolysaccharide peptides (SALP). For the proof-of-concept and screening of different SALP, the peptides were covalently immobilized on glass slides, and the binding of bacteria was confirmed by microscopic examination of the slides or their scanning, in case of fluorescent bacterial cells. The most efficient SALP was further tethered to magnetic beads. SALP beads were used for the magnetic capture of Escherichia coli in liquid samples. The efficiency of this strategy was evaluated using polymerase chain reaction (PCR). Covalently immobilized SALP were capable of capturing bacteria in liquid samples. However, PCR was hampered by the unspecific binding of DNA to the positively charged peptide. We developed a method for DNA recovery by the enzymatic digestion of the peptide, which allowed for a successful PCR, though the method had its own adverse impact on the detection and, thus, did not allow for the reliable quantitative analysis of the pathogen enrichment. Immobilized SALP can be used as capture molecules for bacteria in liquid samples and can be recommended for the design of the assays or decontamination of the fluids. For the accurate subsequent detection of bacteria, DNA-independent methods should be used. Springer-Verlag Berlin Heidelberg, 2015 Sandetskaya N. Nanotechnology Unit, Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany aut Engelmann B. Nanotechnology Unit, Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany aut Brandenburg K. Division of Biophysics, Research Center Borstel, Leibniz-Center for Medicine and Biosciences, Parkallee 10, 23845, Borstel, Germany aut Kuhlmeier D. Nanotechnology Unit, Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany aut European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/8(2015-08-01), 1639-1645 0934-9723 34:8<1639 2015 34 10096 https://doi.org/10.1007/s10096-015-2399-5 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10096-015-2399-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sandetskaya N. Nanotechnology Unit, Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany aut NATIONALLICENCE 700 1- Engelmann B. Nanotechnology Unit, Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany aut NATIONALLICENCE 700 1- Brandenburg K. Division of Biophysics, Research Center Borstel, Leibniz-Center for Medicine and Biosciences, Parkallee 10, 23845, Borstel, Germany aut NATIONALLICENCE 700 1- Kuhlmeier D. Nanotechnology Unit, Fraunhofer Institute for Cell Therapy and Immunology, Perlickstrasse 1, 04103, Leipzig, Germany aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology & Infectious Diseases Springer Berlin Heidelberg 34/8(2015-08-01), 1639-1645 0934-9723 34:8<1639 2015 34 10096